Transforming data to clinical cancer diagnostic decisions in minutes
GenterpretR is accelerating the evolution of Precision Oncology with its technology suite, including OncopretR, OncoBase, and OncoIntelligence that overcome the current challenges of conventional treatments available today.
Challenges with Current Clinical Oncology
~8%
Patients with metastatic cancer are eligible for targeted therapy
1.5%
Patients with relapsed and refractory solid tumors benefit from targeted therapies
0.3 Million
In an RCT comprising 99 patients progression free survival of patients was recorded to be 2.3 months as opposed to 2 months in case of traditional therapies
USD 5-8K
Price range of Foundation Medicine comparison tests for personalized treatment decision making
Genetic testing is increasingly being employed by Oncologists but the gap between test results and response to treatment is currently poor.
Genetic sequencing is expensive and not standardized for effective clinical use. Doctors do not have the training and standards to use genetic data effectively.
Current approaches are based on a handful of known molecular targets (e.g. mutations, copy number, gene fusion), which often fail to find actionable drug targets.
There is variability of responses to current therapy of cancer with side effects form multiple medications, recurrence and metastasis of cancer.
"Data from some 2,600 people enrolled in a sequencing programme at the MD Anderson Cancer Center in Houston, Texas, showed that just 6.4% were paired with a targeted drug for identified mutations"
"When patients with diverse, relapsed cancers are given drugs based on biological markers, only around 30% respond at all, and the median progression-free survival is just 5.7 months"
GenterpretR delivers a game changing approach to precision healthcare with the OncopretR AI Platform
How GenterpretR Works
Current Convention Treatment Path
Step 1: Breast Cancer diagnosis is initiated with a Clinical Examination, PET-SCAN, Histopathology panel tests
Step 2: Oncologists analysis histopathology reports and Image Analysis Reports with observations from radiologists
Steps 3: Oncologists review genetic sequencing reports for selective patients as expenses are high
Step 4: Oncologists identifies the bio-markers and establishes a treatment plan - Resulting in partial, full or no response
GenterpretR’s 3-stage clinical protocol for genetic-based diagnosis, prognosis, and care
Stage 1 - Global evidence search and patient match
Step 1: Patient biopsy samples from the histopathology labs are sent to genetic labs for sequencing
Step 2: Patient sequencing data pipelines are connected to GenterpretR OncoBase data lake
Step 3: Oncologists, physicians and researchers search and match ‘patients like this’ using OncoIntel to understand patients globally with similar diagnosis, prognosis, and drug response
Step 4: The cancer team has clear understanding of potential diagnostic paths, prognosis and treatment options based on global, real-time evidence
Stage 2 - Identify precise alternative therapies, drug matching, and actions
Step 1: Feed patient genetic profile data into pre-trained AI models
Step 2: OncopretR provides oncologists, physicians and researchers with a 360-degree view of patient’s alternative therapy options and drug matches
Step 3: Oncologists, physicians and researchers simulate treatment paths and outcome possibilities with different therapy combinations
Step 4: Make decision to enroll the cancer patient into a live clinical trial process and analyze feedback
Step 5: The cancer team finalizes the treatment plan
Stage 3 - The follow-on care cycle and learning
Step 1: Therapy implementation and monitoring for 3 months
Step 2: Re-run genetic analysis and patient’s therapy response using OncoIntel and OncopretR AI models
Step 3: Fine tune therapy changes and subsequent treatment plan
Step 4: Collaborate with patient to drive a cancer free journey
Live Case Study for Breast Cancer using Genomic Analysis using AI by GenterpretR Team for Non-Responding Patients
Genterpretr Report
Our current studies involves terminally ill breast and lung cancer cases, where no molecular targets are available or the common treatment choices are exhausted. We process complete transcriptome and exome from FFPE and then will apply GenterpretR proprietary algorithms to prioritize therapy with an explanation.
​
The result of the GenterpretR Genomic Analysis is a comprehensive report for oncologists that provides the synthesis of the OncopretR analysis, with full explainability to direct the next best treatment option for the patient. Upon patient consent, suitable therapies will be administered by the doctor and the response will be monitored
OncopretR AI Platform Benefits
Real Time Diagnosis
Real World Evidence
Precision and Optimized Treatment Plans, Increased Survival Rates, Reduction in Relapse
Continuous Benchmarking, Tracking of Disease Progress and Response
GenterpretR Partners
GenterpretR collaborates with leading research teams of global medical institutions, academia, pathological laboratories, and other industry technology companies.
Andromeda 360 AI
Amazon Web Services